-
Ruxolitinib
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Ruxolitinib Myelofibrosis Novartis Oṣu Keje 6, Ọdun 2024 -
Crisaborole
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Crisaborole Atopic Dermatitis ati Àléfọ Pfizer Oṣu Kẹfa Ọjọ 11, Ọdun 2026 -
Relugolix
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Relugolix Akàn pirositeti Takeda ati ASKA Oṣu Kẹta Ọjọ 24, Ọdun 2024 -
Vericiguat
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Vericiguat Ikuna okan Bayer ati MSD May.Ọdun 24, Ọdun 2031 -
Abrocitinib
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Abrocitinib Atopic Dermatitis Pfizer Oṣu kejila 11, Ọdun 2034 -
Rimegepant
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Rimegepant Orififo orififo Biohaven Oṣu kejila ọjọ 22, Ọdun 2031 -
Elagolix 834153-87-6
Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP ElagolixCAS:834153-87-6 Endometriosis Ninu Ile -
Relugolix 737789-87-6
Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Antineoplastic Ninu Ile -
Venetoclax 1257044-40-8
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Venetoclax 1257044-40-8 CLL Abvie Oṣu Kẹta 27,2031 -
Velpatasvir (PVP)
Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP Velpatasvir (PVP) HCV Ninu Ile √ -
Thalidomide
Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP Thalidomide Oogun Onkoloji USP/EP -
Ticagrelor
Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP Ticagrelor Anticoagulant Ninu Ile Ọdun 28984 √